CEL-SCI Co. (CVM) Sees Large Decrease in Short Interest

CEL-SCI Co. (NYSEAMERICAN:CVM) was the target of a large decrease in short interest in the month of January. As of January 31st, there was short interest totalling 643,794 shares, a decrease of 15.3% from the January 12th total of 759,737 shares. Approximately 5.9% of the company’s stock are short sold. Based on an average daily trading volume, of 272,421 shares, the days-to-cover ratio is presently 2.4 days.

Shares of CEL-SCI (NYSEAMERICAN:CVM) traded up $0.07 during midday trading on Friday, hitting $1.82. The company had a trading volume of 311,842 shares, compared to its average volume of 288,169. The stock has a market cap of $22.72, a PE ratio of -1.12 and a beta of -1.49. CEL-SCI has a 1 year low of $1.46 and a 1 year high of $4.00.

CEL-SCI (NYSEAMERICAN:CVM) last issued its quarterly earnings data on Friday, December 29th. The company reported ($0.58) earnings per share for the quarter.

Separately, Dawson James reiterated a “neutral” rating on shares of CEL-SCI in a report on Monday, October 16th.

COPYRIGHT VIOLATION NOTICE: “CEL-SCI Co. (CVM) Sees Large Decrease in Short Interest” was first published by American Banking News and is the property of of American Banking News. If you are viewing this piece on another domain, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be accessed at https://www.americanbankingnews.com/2018/02/09/cel-sci-co-cvm-sees-large-decrease-in-short-interest.html.

CEL-SCI Company Profile

CEL-SCI Corporation is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The Company is focused on activating the immune system to fight cancer and infectious diseases. It operates through the segment of research and development of certain drugs and vaccines.

Receive News & Ratings for CEL-SCI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CEL-SCI and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply